New York, USA · Est. 2024

US-Based
Peptide Supplier

Acurion assembles exclusive pharmaceutical supply chains across the full peptide portfolio — GLPs, metabolic peptides, longevity peptides, and beyond — connecting GMP-certified manufacturers with emerging markets worldwide.

Partner With Us Our Portfolio

Countries with no
GLP patent barrier

Generic next-gen GLP
available globally today

Molecules
in pipeline

Active markets
USA · MENA · Brazil · Gulf

About

Who We Are

Acurion Holdings LLC is a US-based pharmaceutical trading company, incorporated in New York. We supply GMP-certified peptides — GLP analogues, longevity peptides, regenerative peptides — to clinics, distributors and institutional buyers. Our supply chain reaches from GMP-certified manufacturing partners on the West Coast, USA and in South Korea and Taiwan, through our New York and Hong Kong hubs, to partners across the United States, MENA, Latin America, and the Gulf.

01 — Infrastructure

Exclusive Supply Chain

Contractual exclusivity at every level — API and finished product. GMP manufacturing partners in the USA (West Coast) and Asia. US entity at the front — New York headquarters, Hong Kong and Dubai subsidiaries.

02 — Expertise

Regulatory Intelligence

Deep mastery of ANVISA and international reliance pathways. Parallel filing strategies that compress time-to-market by 12 to 18 months versus conventional approaches.

03 — Access

Market Access Network

Active partnerships across MENA, Latin America, and the Gulf. A full peptide catalogue — GLP analogues, longevity peptides, regenerative peptides. First-mover positioning in markets others have not reached.

Leadership

Founded & led by a PharmD

Serial entrepreneur with deep regulatory and scientific fluency across pharmaceutical trading, biotech, and life sciences. International operations spanning Europe, MENA, and Latin America.

Portfolio

Full Peptide Portfolio.
Metabolic, Longevity & Beyond.

Acurion supplies the full spectrum of GMP-certified peptides — from GLP analogues (Semaglutide, Tirzepatide, Retatrutide) to longevity and regenerative peptides (BPC-157, TB-500, MOTS-c, Epithalon, GHK-Cu, Tesamorelin, CJC-1295/Ipamorelin). Two lead molecules are positioned for immediate market entry. The full catalogue is available under NDA.

All GLPs — Metabolic Portfolio

All GLP
Analogues

Semaglutide, Tirzepatide, Retatrutide and more — once-weekly SC autoinjector pens and vials. Patent cleared in target markets. PIC/S GMP-certified.

Extended Portfolio — Longevity & Regenerative

Specialty
Peptides

BPC-157, TB-500, MOTS-c, Epithalon, GHK-Cu, Tesamorelin, CJC-1295/Ipamorelin and more. Lyophilized vials. GMP-certified. Full catalogue under NDA.

NDA

GLP analogues delivered via once-weekly SC autoinjector pen or vial. Specialty peptides supplied as lyophilized vials. All products sourced from GMP / PIC/S-certified manufacturers. Full catalogue, pricing, and COA samples disclosed exclusively following NDA execution.

Geography

Where We Operate

Acurion's primary market is the United States. Internationally, we target markets at the intersection of high unmet need, limited patent protection, and established distribution infrastructure.

Primary Market — Active

🇺🇸

United States

Clinics, MedSpas, compounding pharmacies
Telehealth platforms and institutional buyers
GMP-certified partner on the West Coast, USA
US entity — New York headquarters
Domestic supply chain depth

Our primary and largest market.

Active — Initiated

🌍

MENA Region

High diabetes and obesity prevalence
Favorable patent landscape for generic GLP entry
Acurion as Marketing Authorization Holder
Expedited reliance registration pathway
Private pharmacy and institutional channels

Significant unmet need — no patent barrier.

Active — Initiated

🇧🇷

Brazil

R$15.6 billion GLP market (2026 projection)
Primary molecule patent expired — March 2026
ANVISA dossier in preparation
Parallel regulatory strategy
First-wave generic submission

First generic wave post-expiry.

Pipeline — 2025/2026

🇦🇪

Gulf / UAE

FDA/EMA reliance — accelerated pathway
Dubai DIFC/DMCC subsidiary planned
High private-pay market
Strong institutional procurement
Hong Kong hub for Asia-Pacific

Premium private market entry.

Standards

GMP Manufacturing

Products are manufactured by GMP-certified partners across the USA (West Coast) and Asia (South Korea, Taiwan) — the same standards that supply regulated markets globally. Manufacturer identities disclosed under NDA.

Fill & Finish — PIC/S GMP

Autoinjector Pen Assembly Line

Analytical Testing

Quality Control Laboratory

USA + Asia

GMP-certified manufacturing partners on the West Coast, USA and in South Korea and Taiwan. Same standards that supply regulated markets globally.

2–8°C

Validated cold chain from manufacturing to destination port. Temperature monitoring on all shipments — no compromise on product integrity.

13 wk

Average lead time from purchase order to destination port. Manufacturing, QC release, and sea freight fully coordinated end-to-end.

Infrastructure

The Acurion Supply Chain

A fully coordinated, exclusive trading structure — from GMP source to market-ready product. No factory. No warehouse. Maximum agility and first-mover speed.

01 — Source

API Manufacturer

Asia · Confidential
GMP / NMPA certified

→

02 — Production

Finished Product Manufacturers

West Coast, USA · Korea / Taiwan
GMP · PIC/S certified

→

03 — US Entity

Acurion Holdings LLC

New York, USA
HK · Dubai subsidiaries

→

04 — Market

Local Partner

MAH / Importer
Distribution network

Exclusivity Structure

Acurion holds contractual exclusivity with both the API manufacturer and the finished product manufacturer. Your competition cannot access the same chain. Territory rights granted per market.

Confidentiality

Manufacturer identities and proprietary supply chain details remain strictly confidential. Full disclosure following NDA execution only. All partner inquiries treated with strict commercial confidentiality.

Why Acurion

What We
Bring to the Table

We are not a vendor. We are a strategic partner — entering markets before competition arrives, holding the authorizations, and succeeding only when you do.

Exclusive Supply Chain

Secured contractual exclusivity at every level — API and finished product. No competitor can replicate your supply chain.

First-Mover Positioning

We identify and enter markets before competition arrives. Our active programs are among the first generic GLP entries in those markets.

Authorization Control

Acurion holds or co-holds marketing authorizations — protecting your investment and ensuring uninterrupted supply throughout the lifecycle.

Full Peptide Catalogue

GLP analogues, longevity peptides, regenerative peptides — full portfolio from a single exclusive partner. One chain, many molecules.

Lean & Fast

No factory. No warehouse. Acurion coordinates the full chain with precision — 13 weeks from purchase order to destination port.

Aligned Incentives

Acurion's commercial success is tied directly to yours. Long-term exclusive agreements align interests across the full product lifecycle.

Get in Touch

Partner With
Acurion

We are seeking exclusive distribution partners in select markets. If you represent a pharmaceutical importer, distributor, or investment group with market access, we want to hear from you.

EntityAcurion Holdings LLC
US Address36 Peck Slip, New York, NY 10038-1753
InternationalHong Kong SAR · Dubai, UAE
Phone+1 (602) 399-5298
Emailcontact@acurionpeptides.com

All inquiries treated with strict confidentiality. Manufacturer identities and supply chain details disclosed exclusively following NDA execution.

GMP Peptide Supplier
Full-Spectrum Portfolio

Acurion Peptides LLC is an international GMP peptide supplier and pharmaceutical trading company headquartered in Hong Kong. We supply the full spectrum of GMP-certified peptides — including all GLP analogues (Semaglutide, Tirzepatide, Retatrutide), BPC-157, TB-500, MOTS-c, Epithalon, GHK-Cu, Tesamorelin, and CJC-1295/Ipamorelin — to institutional partners, distributors, and importers worldwide.

Our peptide supply chain connects PIC/S-certified finished-product manufacturers in South Korea and Taiwan with partners across MENA, Latin America, and the Gulf region. All peptide molecules are sourced from GMP-certified API manufacturers and delivered as ready-to-market autoinjector pens or vials.

As a dedicated generic peptide supplier, Acurion holds contractual exclusivity with its manufacturing partners — ensuring that no competing distributor can access the same supply chain in your territory.

Peptide Supply — Key Capabilities

—GMP-certified peptide API sourcing (NMPA, PIC/S)
—GLP analogues (Semaglutide, Tirzepatide, Retatrutide) — SC injection
—Autoinjector pen and lyophilized vial formats
—Validated 2–8°C cold chain supply — CIF delivery
—Regulatory dossier support — ANVISA, EDA, MOHAP
—Marketing Authorization Holder (MAH) capability
—Exclusive territory distribution agreements
—Lead time 13 weeks — purchase order to destination port

Acurion Peptides LLC · GMP Peptide Supplier · Hong Kong SAR · contact@acurionpeptides.com

US-BasedPeptide Supplier